The 10 abstracts selected here are actually not in order of magnitude, preference or weight… with the lone exception #1, an incredible piece of work that was a decade in the making.
Few of these choices are in the press briefing, none are in the Plenary session – they’re often hidden gems that many will miss in the hurly burly of the data drop and noise.
They’re also 10 abstracts that I feel are worthy of highlighting with some additional commentary.
Some of the ideas here illustrate some intriguing trends that are emerging, others may have a big impact on the cancer immunotherapy space, either because of the novel concept idea, or because the data are very compelling, if you understand the science.
You can decide for yourselves – which ones would you pick and why?
Subscribers can log-in or you can sign up in the Blue Box below to learn more about the important cancer immunotherapy abstracts at ASCO 2016…
Dr Jérôme Galon is a leading Immunologist and Research Director at INSERM in Paris.
At the recent European Cancer Congress in Vienna he gave an engaging presentation in the scientific symposium on Cellular Immunotherapy of Cancer.
Afterwards, Dr Galon (pictured right) kindly spoke to BSB about:
- What is immunosurveillance?
- How the type, location and density of immune cells present within tumors predicts clinical outcome.
- The potential of the Immunoscore assay to classify cancers based on their immune profile
- What the future may hold in terms of personalized cancer immunotherapy.
One only has look at the impressive list of companies for which Dr Galon is a consultant or scientific adviser to see how valued his work in the cancer immunotherapy field is; it was a privilege to talk with him. The excerpts of the in-depth interview he kindly gave make for a good weekend read!
Grab a coffee & bagel and enjoy!
Subscribers can login to read more or you can purchase access below.